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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Nearly all published studies of recurrent Clostridium difficile
infections (CDI) report recurrent CDI within 8 weeks after the primary infection. This study
explored the molecular characteristics of C. difficile isolates from the first recurrent CDI more
than 8 weeks after the primary infection.
Methods: Consecutive hospitalized patients with a recurrent CDI more than 8 weeks after a pri-
mary infection were enrolled prospectively from January 2008 to February 2011. All C. difficile
isolates of the primary and recurrent infections were collected and subjected to polymerase
chain reaction ribotyping and antimicrobial susceptibility testing.
Results: There were 62 cases of CDI in this study, which included 32 cases (51.6%) of recur-
rence due to the same ribotype of C. difficile, 26 (41.9%) cases due to a different ribotype,
and four (6.5%) cases with 2e4 recurrences due to the same or different strains. One hundred
and forty C. difficile isolates were obtained, which included 62 primary CDI isolates and 78
recurrent isolates. Ribotype 020 was the most common C. difficile strain in primary and recur-
rent infections. Ribotype 001 accounted for 15.4% (10/78) of recurrent infections and 3.2% (2/
62) of primary infections (p Z 0.0447). The minimum inhibitory concentration at 90% (MIC90)intraub, F68 Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. Minggui Wang,
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10.1016/j.jmii.2015.10.017values of linezolid, moxifloxacin, and clindamycin against type 001 strains were much higher,
compared to the three other common ribotypes.
Conclusion: Recurrent CDI more than 8 weeks after a primary infection can be caused by the
same or different C. difficile ribotype at similar percentages. Ribotype 001 C. difficile strains,
which have a lower susceptibility to antimicrobials, were isolated more frequently in patients
with a recurrent CDI.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Clostridium difficile is a strictly anaerobic, spore-forming,
Gram-positive bacillus. It colonizes the human intestinal
tract and multiplies after the resident flora has been
altered by treatment with broad-spectrum antibiotics.
Clostridium difficile releases two exotoxins (i.e., A and B)
and/or a binary toxin, and cause C. difficile infection (CDI)
symptoms such as antibiotic-associated diarrhea and
pseudomembranous colitis.1,2 The epidemiology of CDI has
undergone many changes since the beginning of this cen-
tury. In the United States, the reported CDI incidence in
2005 (85 per 100,000 population) was nearly three times
greater than the incidence in 1996 (31 per 100,000 popu-
lation).3 In the United Kingdom, CDI was listed as the pri-
mary cause of death for 3393 patients in 2006, which was
seven times greater than the 499 deaths in 1999.4
Furthermore, the endemic C. difficile ribotype 027 strain
caused sporadic outbreaks.4
Clostridium difficile is highly susceptible to antibiotics
that are in common use; however, treatment failure and
the recurrence of infection are problematic. Even when the
primary CDI is cured, recurrent CDI occurs within 8 weeks in
6e25% of patients.5e7 For patients with at least one
recurrence, the risk of a second recurrence is 45% and the
risk of a third recurrence is 65%.6,8 Recurrent CDI is a
burden for patients because it increases morbidity and di-
minishes the quality of life in affected individuals.
Furthermore, it can be fatal and has a huge economical
cost.6 The cost of recurrent CDI in the United States was
US$7.1 billion in 2009, which was nearly seven times the
cost for primary CDI (US $1.1 billion).9
Most recurrences occurred within 30 days or as late as
8 weeks after the primary infection.6,10e14 To date, only
one study has reported that CDI recurrence can occur after
8 weeks, raising the caveat that misclassification could in-
fluence epidemiological statistics.15 We aimed to reveal the
molecular characteristics of C. difficile isolates from pa-
tients with the first recurrent CDI more than 8 weeks after
the primary CDI.
Methods
Case collection and bacterial isolates
This prospective study was conducted at the Karolinska
Institutet Hospital Huddinge in Stockholm, Sweden.Chen Y, et al., Molecular charact
the primary infection, Journal of MConsecutive cases of CDI from hospitalized patients were
followed up proactively for at least 30 months. The patients
with recurrence after 8 weeks were collected from January
2008 to February 2011, whereas patients without a recur-
rence or with a recurrence within 8 weeks of the primary
CDI were excluded. All toxigenic C. difficile isolates (i.e.,
toxin B-positive, evaluated by cell cytotoxicity neutraliza-
tion assay) of the primary and recurrent CDI were collected
in the clinical microbiology department and stored at
80C.
Ribotyping of C. difficile isolates
Bacterial cells were obtained from C. difficile cultured
anaerobically in a peptone/yeast extract medium for 1 day.
Chelex 100 resin (Bio-Rad, Sundbyberg, Sweden) was added
[5% (w/v) final concentration] after centrifugation at
13,000 rpm (17,900 rcfg) for 5 minutes. The mixture was
heated at 96C for 10 minutes and the template nucleic
acid was obtained by another centrifugation at 13,000 rpm
(i.e., 17,900 rcfg) for 2 minutes. Polymerase chain reac-
tion was targeted to the 16S-23S rRNA gene intergenic
spacer region.16 Electrophoresis and staining procedures
were performed using the Genephor Electrophoresis Unit
and Silver Staining Kit (GE Healthcare AB, Danderyd, Swe-
den). Bionumerics Software (Applied Maths, Sint-Martens-
Latem, Belgium) was used to compare the molecular fin-
gerprints with those in the local database to determine the
C. difficile ribotypes.
Antimicrobial susceptibility testing
The minimal inhibitory concentrations (MICs) of 10 antimi-
crobial agents against 140 C. difficile isolates were deter-
mined by the agar dilution method, which followed the
procedures recommended by Approved Standard M11-A8 of
the Clinical Laboratory Standard Institute (CLSI).17 The
breakpoints of metronidazole, vancomycin, rifampicin,
tigecycline, and fusidic acid were referenced to the Euro-
pean Committee on Antimicrobial Susceptibility Testing
(EUCAST) Clinical Breakpoint, Version 5.0.18 The break-
points of moxifloxacin, clindamycin, and tetracycline were
referred to CLSI M11-A8. C. difficile ATCC700057, Bacter-
oides fragilis ATCC25285, Enterococcus faecalis
ATCC29212, Staphylococcus aureus ATCC29213, and Bac-
teroides thetaiotaomicron ATCC29741 were used as refer-
ence strains.eristics of Clostridium difficile strains from patients with a first
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
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Descriptive analysis was used for continuous variables.
Pearson’s c2 test and Fisher’s exact test were used for
comparative analysis of the categorical variables. All data
analyses were conducted using SPSS 18.0 software (SSPS
Inc., Chicago, IL, USA) and statistical significance was set at
p  0.05.
Results
Sixty-two patients with recurrent CDI were enrolled: 51
patients had a single recurrence; eight patients, two re-
currences; two patients, three recurrences; and one pa-
tient, four recurrences. The patients’ ages ranged from
20 years to 99 years and 72.6% (45/62) were older than
65 years. Among the 62 patients, 32 (51.6%) patients had a
total of 42 episodes of recurrent infections due to the same
ribotype as the pathogen that caused the primary infection,
and 26 (41.9%) patients (representing 36 episodes) had
recurrent infections due to a ribotype other than that of
the primary infection. Four (6.5%) patients had more than
one recurrence (resenting 11 episodes in all) caused by the
same or different C. difficile ribotype. Patients with a
primary infection caused by C. difficile ribotype 020, SE21,
or 023 more often experienced a recurrent infection due to
the same type as the primary infection rather than by
another ribotype. For example, eight of 10 patients infec-
ted by ribotype 020 had recurrences due to ribotype 020
and two of 10 recurrences were caused by other ribotypes.
However, this difference was not statistically significant
(p Z 0.097; Table 1).
In all, 140 isolates of C. difficile were obtained. These
included 78 recurrent isolates and 62 isolates that caused
the primary infection. The latter isolates belonged to 30
ribotypes, and type 020 was most common (16.1%, 10/62),
and types SE21 and 231 each accounted for 8.1% (5/62). The
78 recurrent isolates belonged to 31 ribotypes, and type
020 was most common (17.9%, 14/78), followed by ribotype
001 (12.8%, 10/78) and ribotype 023 (6.4%, 5/78). RibotypeTable 1 The distribution of ribotypes of 140 Clostridium diffic
patients.
Primary infection Recurrences with the same r
Ribotype Cases
n (%)
Cases
n (%)
Episode
n (%)
020 10 (16.1) 8 (22.2) 10 (23.
SE21 5 (8.1) 4 (11.1) 4 (9.5
231 5 (8.1) 3 (8.3) 3 (7.1
002 3 (4.8) 2 (5.6) 2 (4.8
023 3 (4.8) 3 (8.3) 5 (11.
SE14 2 (3.2) 2 (5.6) 2 (4.8
001 2 (3.2) 2 (5.6) 2 (4.8
SE19 m 2 (3.2) 2 (5.6) 2 (4.8
014/077 2 (3.2) 0 (0.0) 0 (0.0
Others 28 (45.2) 10 (27.8) 12 (28.
Total 62 (100) 36 (100.0) 42 (100
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10.1016/j.jmii.2015.10.017001 isolates were obtained from 15.4% (10/78) of recurrent
isolates and 3.2% (2/62) of 62 isolates that caused primary
infections (p Z 0.0447). The highly virulent, epidemic
ribotype 027 was not detected in this study.
The in vitro antimicrobial susceptibility study showed
that all 140 C. difficile isolates were susceptible to
metronidazole, vancomycin, and fusidic acid (Table 2). The
resistance rates of rifampicin, tigecycline, tetracycline,
moxifloxacin, and clindamycin was 1.4%, 1.4%, 3.6%, 14.3%,
and 92.1%, respectively. The minimum inhibitory concen-
tration at 90% (MIC90) value of linezolid and fidaxomicin was
2 mg/L and 0.125 mg/L, respectively. There was no dif-
ference between the resistance rates of C. difficile isolates
in the primary infection isolates and recurrent isolates
(Table 2).
The MIC values of major ribotypes 020, 001, SE21, and
023 are listed in Table 3. The MIC90 values of ribotype 001
for linezolid, moxifloxacin, and clindamycin were higher
than those of ribotypes 020, SE21, and 023. By contrast, the
MIC90 value of ribotype 001 was lower than that of the other
three ribotypes for fidaxomicin.Discussion
Clostridium difficile infection is a major public health
problem worldwide. Several factors are associated with CDI
such as ingested C. difficile spores remaining in the gut,
destruction of the normal flora, and a lack of specific im-
munity to the bacteria. However, the bacteria have lower
resistance rates to commonly used antibiotics, but recur-
rence occurred frequently. There was no apparent corre-
lation between recurrence and bacterial resistance.4,12
Almost all published studies have focused on CDI recur-
rence within 8 weeks after a primary infection.6,10e14 In
1998, Wilcox et al19 reported recurrent CDI cases in England
in which the first recurrence occurred between 5 days and
2 months after a primary infection. Among 55 eligible
cases, the rate of reinfection (i.e., recurrence with
different ribotypes of C. difficile; 56%, 15/27) was numer-
ically greater than the rate of relapse (i.e., recurrence withile isolates causing primary infections and recurrences in 62
ibotype Recurrences with different ribotype
s Cases
n (%)
Episodes
n (%)
8) 2 (6.7) 3 (8.3)
) 1 (3.3) 2 (5.6)
) 2 (6.7) 2 (5.6)
) 1 (3.3) 1 (2.8)
9) 0 (0.0) 0 (0.0)
) 0 (0.0) 0 (0.0)
) 1 (3.3) 2 (5.6)
) 0 (0.0) 0 (0.0)
) 2 (6.7) 2 (5.6)
6) 21 (70.0) 24 (66.7)
.0) 30 (100.0) 36 (100.0)
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Table 2 Comparison of antimicrobial susceptibility of 10 antimicrobial agents against 62 Clostridium difficile isolates causing
primary infections and 78 isolates causing recurrent infections.
Antimicrobial agents Resistance breakpoint (mg/mL) MIC90 (mg/mL) Resistance rate (%)
All Primary Recurrent All Primary Recurrent
(n Z 140) (n Z 62) (n Z 78) (n Z 140) (n Z 62) (n Z 78)
Metronidazole >2 a 0.5 0.5 0.5 0 0 0
Vancomycin >2 a 0.5 0.5 0.5 0 0 0
Rifampicin >0.004 a 0.004 0.004 0.004 1.4 1.6 1.3
Linezolid NA 2 2 2 d d d
Fidaxomicin NA 0.125 0.125 0.125 d d d
Moxifloxacin 8 b 32 32 32 14.3 16.1 12.8
Clindamycin 8 b >128 >128 >128 92.1 87.1 96.2
Tigecycline >0.25 a 0.125 0.125 0.125 1.4 1.6 1.3
Tetracycline 16 b 0.25 0.5 0.25 3.6 4.8 2.6
Fusidic acid >2 a 1 1 1 0 0 0
a Information from Breakpoint tables for interpretation of MICs and zone diameters, version 5.0 by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST).18
b Information from Methods for antimicrobialsusceptibility testing of anaerobic bacteria. Approved standard M11-A8 by the Clinical
and Laboratory Standards Institute (CLSI).17
MIC90 Z minimum inhibitory concentration at 90%.
Table 3 The MIC90 values and resistance rates of four major ribotypes of Clostridium difficile isolates.
Antimicrobial
agents
Resistance
breakpoint,
mg/mL
MIC90 (mg/mL) Resistance rate (%)
Ribotype
020
Ribotype
001
Ribotype
SE21
Ribotype
023
Ribotype
020
Ribotype
001
Ribotype
SE21
Ribotype
023
(n Z 24) (n Z 12) (n Z 10) (n Z 10) (n Z 24) (n Z 12) (n Z 10) (n Z 10)
Metronidazole >2 a 0.5 1 0.5 0.5 0 0 0 0
Vancomycin >2 a 0.5 1 0.5 0.5 0 0 0 0
Rifampicin >0.004 a 0.004 0.004 0.004 0.004 4.2 0 0 0
Linezolid NA 2 8 2 2 d d d d
Fidaxomicin NA 0.125 0.032 0.125 0.125 d d d d
Moxifloxacin 8 b 2 32 2 2 8.3 25 0 0
Clindamycin 8 b 16 >128 16 16 100 83.3 100 80
Tigecycline >0.25 a 0.064 0.064 0.125 0.064 0 0 0 0
Tetracycline 16 b 0.125 0.25 0.125 0.125 0 0 0 0
Fusidic acid >2 a 0.5 0.5 0.5 0.5 0 0 0 0
a Information from Breakpoint tables for interpretation of MICs and zone diameters, version 5.0 by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST).18
b Information from Methods for antimicrobialsusceptibility testing of anaerobic bacteria. Approved standard M11-A8 by the Clinical
and Laboratory Standards Institute (CLSI).17
MIC90 Z minimum inhibitory concentration at 90%.
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ported that relapse with the original strain occurred in
66.7% patients in the United States in which recurrence
occurred mostly < 5 weeks after a primary infection.
To date, there has been a paucity of literature con-
cerning CDI recurrence more than 8 weeks after a primary
infection.15,20 Kamboj et al15 reported recurrence more
than 8 weeks; however, specific C. difficile ribotypes were
not identified. In this study, a similar percentage of recur-
rent CDI occurring more than 8 weeks after a primary
infection was caused by the same ribotype isolate (51.6%)
or a different ribotype isolate (41.9%). The most common C.Please cite this article in press as: Chen Y, et al., Molecular charact
recurrence more than 8 weeks after the primary infection, Journal of M
10.1016/j.jmii.2015.10.017difficile ribotype was 020 in the primary and recurrent
CDIs. The patients whose primary infections were caused by
ribotype 020 were more likely to have a recurrence with the
same ribotype. Magnusson et al21 reported that ribotype
001 was the most common isolate in nosocomially acquired
CDIs, and it was prone to cause relapse (i.e., recurrence
with the same ribotypes). Ribotype 001, the second most
common ribotype in recurrent infections in this study, was
isolated more frequently in recurrent infections (15.4%)
than in primary infections (3.2%, p < 0.05).
The drawbacks of this study are that the clinical data of
patients with a recurrent CDI more than 8 weeks after theeristics of Clostridium difficile strains from patients with a first
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
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characteristics and prognosis of these patients in compari-
son to patients with recurrent CDI within 8 weeks were
lacking.
All 140 C. difficile isolates in this study were susceptible
to metronidazole and vancomycin, which is consistent with
the finding in other reports.4,22 The MIC90 values of ribotype
001 to linezolid, moxifloxacin, and clindamycin were higher
than those of the other ribotypes. A recent study demon-
strated that low-molecular-weight S layer proteins of
ribotype 001 strains showed 88% identity with the proteins
of ribotype 027, which is a hypervirulent strain, and causes
outbreaks and recurrent CDIs worldwide.23 Furthermore,
low-molecular-weight S layer proteins are immunodo-
minant antigens, which may have a role in attacking
hosts.23
In summary, a recurrent CDI more than 8 weeks after the
primary infection could be caused by the same or different
C. difficile ribotypes at similar percentages. Ribotype
001 C. difficile strains were isolated more frequently in
recurrent CDI patients. Further studies are needed to
explore the clinical characteristics of patients with recur-
rent CDI occurring more than 8 weeks after the primary
infection, compared to the characteristics of patients with
recurrent infection occurring within 8 weeks.
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